Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.

Detalhes bibliográficos
Autor(a) principal: Félix, Jorge M
Data de Publicação: 2005
Outros Autores: Inês, Mónica S, Acosta, Cátia M
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000
Resumo: This article explores the application of cost-effectiveness analyses to the use of triptanes (5-HT1 Serotonin agonist) in the pharmacologic treatment of migraine, on the primary and secondary health care, in Portugal. The cost-effectiveness of oral eletriptan (40 and 80 mg) is compared to two matrices defined by the consumption of naratriptan (2.5 mg), sumatriptan (50 and 100 mg) and zolmitriptan (2.5 and 5 mg). The effectiveness vector was calculated based on the time without incapacity caused by migraine. The costs reflect the society perspective. We concluded that the utilization of eletriptan allows health gains with cost reduction in the treatment of migraine, and thereby can be considered a cost-effective alternative to the other oral triptans co-financed by the Portuguese National Health Service.
id RCAP_b9ba168ac9d985380ad2f11343cec7ec
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/1000
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.Análise probabilística de custo-efectividade: utilização do eletriptano no tratamento das crises de enxaqueca em Portugal.This article explores the application of cost-effectiveness analyses to the use of triptanes (5-HT1 Serotonin agonist) in the pharmacologic treatment of migraine, on the primary and secondary health care, in Portugal. The cost-effectiveness of oral eletriptan (40 and 80 mg) is compared to two matrices defined by the consumption of naratriptan (2.5 mg), sumatriptan (50 and 100 mg) and zolmitriptan (2.5 and 5 mg). The effectiveness vector was calculated based on the time without incapacity caused by migraine. The costs reflect the society perspective. We concluded that the utilization of eletriptan allows health gains with cost reduction in the treatment of migraine, and thereby can be considered a cost-effective alternative to the other oral triptans co-financed by the Portuguese National Health Service.This article explores the application of cost-effectiveness analyses to the use of triptanes (5-HT1 Serotonin agonist) in the pharmacologic treatment of migraine, on the primary and secondary health care, in Portugal. The cost-effectiveness of oral eletriptan (40 and 80 mg) is compared to two matrices defined by the consumption of naratriptan (2.5 mg), sumatriptan (50 and 100 mg) and zolmitriptan (2.5 and 5 mg). The effectiveness vector was calculated based on the time without incapacity caused by migraine. The costs reflect the society perspective. We concluded that the utilization of eletriptan allows health gains with cost reduction in the treatment of migraine, and thereby can be considered a cost-effective alternative to the other oral triptans co-financed by the Portuguese National Health Service.Ordem dos Médicos2005-02-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000oai:ojs.www.actamedicaportuguesa.com:article/1000Acta Médica Portuguesa; Vol. 18 No. 1 (2005): January-February; 77-87Acta Médica Portuguesa; Vol. 18 N.º 1 (2005): Janeiro-Fevereiro; 77-871646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000/669Félix, Jorge MInês, Mónica SAcosta, Cátia Minfo:eu-repo/semantics/openAccess2022-12-20T10:57:17Zoai:ojs.www.actamedicaportuguesa.com:article/1000Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:16:54.001280Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
Análise probabilística de custo-efectividade: utilização do eletriptano no tratamento das crises de enxaqueca em Portugal.
title Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
spellingShingle Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
Félix, Jorge M
title_short Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
title_full Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
title_fullStr Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
title_full_unstemmed Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
title_sort Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal.
author Félix, Jorge M
author_facet Félix, Jorge M
Inês, Mónica S
Acosta, Cátia M
author_role author
author2 Inês, Mónica S
Acosta, Cátia M
author2_role author
author
dc.contributor.author.fl_str_mv Félix, Jorge M
Inês, Mónica S
Acosta, Cátia M
description This article explores the application of cost-effectiveness analyses to the use of triptanes (5-HT1 Serotonin agonist) in the pharmacologic treatment of migraine, on the primary and secondary health care, in Portugal. The cost-effectiveness of oral eletriptan (40 and 80 mg) is compared to two matrices defined by the consumption of naratriptan (2.5 mg), sumatriptan (50 and 100 mg) and zolmitriptan (2.5 and 5 mg). The effectiveness vector was calculated based on the time without incapacity caused by migraine. The costs reflect the society perspective. We concluded that the utilization of eletriptan allows health gains with cost reduction in the treatment of migraine, and thereby can be considered a cost-effective alternative to the other oral triptans co-financed by the Portuguese National Health Service.
publishDate 2005
dc.date.none.fl_str_mv 2005-02-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000
oai:ojs.www.actamedicaportuguesa.com:article/1000
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/1000
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1000/669
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 18 No. 1 (2005): January-February; 77-87
Acta Médica Portuguesa; Vol. 18 N.º 1 (2005): Janeiro-Fevereiro; 77-87
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130622947491840

Registros relacionados